CD274 and non-small cell lung carcinoma: In NSCLC, in most cases, only PD‐L1 expression on tumor cells (fraction of tumor proportion; percentage of positive cells expressing membrane staining) was associated with a predictive biomarker of immune checkpoint inhibitor therapy.21